These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15190926)

  • 1. Shrinking waters in the safe harbor: has Integra Lifesciences v. Merck turned the tide by narrowing available exempted infringing uses?
    Davison AM
    Food Drug Law J; 2004; 59(1):79-92. PubMed ID: 15190926
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Canadian perspective: trends in drug and medical device class actions in Canada.
    Vernon W
    Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
    [No Abstract]   [Full Text] [Related]  

  • 4. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 5. Ejecting the FDA from the courtroom.
    Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
    [No Abstract]   [Full Text] [Related]  

  • 6. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 7. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
    Manthei JR; Hathaway CR; Grant MA; Chung DD
    Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
    [No Abstract]   [Full Text] [Related]  

  • 10. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 11. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 12. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical device reporting: issues with Class III medical devices.
    Zigler J; Walsh J; Zigler J
    Food Drug Law J; 2007; 62(3):573-80. PubMed ID: 17915398
    [No Abstract]   [Full Text] [Related]  

  • 14. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 15. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 17. Left to their own devices: breakdowns in United States medical device premarket review.
    Hines JZ; Lurie P; Yu E; Wolfe S
    PLoS Med; 2010 Jul; 7(7):e1000280. PubMed ID: 20634922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 19. The Medical Device Safety Act of 2009.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Apr; 360(15):1550-1. PubMed ID: 19297562
    [No Abstract]   [Full Text] [Related]  

  • 20. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.